@Westermarcklab
@westermarcklab.bsky.social
#CIP2A and #Phosphatase biology for cancer therapy @TurkuBioscience @UniTurku
#PP2A #MYC #PME-1 #RAS #Breastcancer #TNBC #Epigenetics
https://bioscience.fi/research/cancer-cell-signaling
https://publons.com/researcher/3571657/jukka-westermarck/
#PP2A #MYC #PME-1 #RAS #Breastcancer #TNBC #Epigenetics
https://bioscience.fi/research/cancer-cell-signaling
https://publons.com/researcher/3571657/jukka-westermarck/
2/2 These results potentially facilitate development of CIP2A inhibitor molecules for therapies in #BRCA mutant cancers, other CIP2A-dependent cancers and in #Alzheimer disease. Very exciting collaboration with groups of Olli Pentikäinen and Ulla Pentikäinen and led by Karolina Pavic.
October 15, 2025 at 5:57 AM
2/2 These results potentially facilitate development of CIP2A inhibitor molecules for therapies in #BRCA mutant cancers, other CIP2A-dependent cancers and in #Alzheimer disease. Very exciting collaboration with groups of Olli Pentikäinen and Ulla Pentikäinen and led by Karolina Pavic.
The beautiful image was taken by senior scientist Mari Peltola as part of Thestra´s R&D process to introduce the EPLINEx (the trade name for proprietary LIMA1 assay) IHC assay for clinical #HNSCC diagnostics.
Stay tuned: thestra.fi
Stay tuned: thestra.fi
Cancer diagnostics company | Thestra
We are a cancer diagnostics company which translates high quality academic research results to patient specific companion diagnostics and therapy stratification solutions.
thestra.fi
August 11, 2025 at 10:50 AM
The beautiful image was taken by senior scientist Mari Peltola as part of Thestra´s R&D process to introduce the EPLINEx (the trade name for proprietary LIMA1 assay) IHC assay for clinical #HNSCC diagnostics.
Stay tuned: thestra.fi
Stay tuned: thestra.fi
The results are currently to be turned to a routine IHC diagnostic assay by our Start-up company Thestra Ltd. and we aim to bring the assay to clinical use by 2026.
Stay tuned!
thestra.fi/scientific-b...
Stay tuned!
thestra.fi/scientific-b...
Scientific background of Thestra´s EPLINEx™ method in HNSCC diagnosis reported in EMBO Molecular Medicine | Thestra
Scientific background of Thestra´s EPLINEx™ method is reported in EMBO Molecular Medicine, a leading medical journal. The findings were validated across all Finnish university hospitals on the use of...
thestra.fi
July 23, 2025 at 7:42 AM
The results are currently to be turned to a routine IHC diagnostic assay by our Start-up company Thestra Ltd. and we aim to bring the assay to clinical use by 2026.
Stay tuned!
thestra.fi/scientific-b...
Stay tuned!
thestra.fi/scientific-b...
Based on two prospective cohorts, none of the LIMA1-alpha negative HNSCC patients with non-metastatic disease upon diagnosis died during the follow-up.
July 23, 2025 at 7:42 AM
Based on two prospective cohorts, none of the LIMA1-alpha negative HNSCC patients with non-metastatic disease upon diagnosis died during the follow-up.
Ps. Some PIs can brag about their 1 million € sequencers, I only got a 100€ sticker printer😅
June 26, 2025 at 10:15 AM
Ps. Some PIs can brag about their 1 million € sequencers, I only got a 100€ sticker printer😅
Stunning work! Huge Congrats @kusterlab.bsky.social
May 23, 2025 at 2:41 AM
Stunning work! Huge Congrats @kusterlab.bsky.social